| Atorvastatin | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | |
| Atorvastatin | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Atorvastatin | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Atorvastatin | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Atorvastatin | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Atorvastatin | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | |
| Atorvastatin | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Atorvastatin | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | |
| Atorvastatin | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | |
| Atorvastatin | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | |
| Atorvastatin | hsa03013 | RNA transport | 6.93E-08 | 16 | O14980, P52298, O14893, P61326, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, P20042, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF2S2, EIF4A2, EIF4B, TACC3 | More | |
| Atorvastatin | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | |
| Atorvastatin | hsa03040 | Spliceosome | 3.98E-02 | 4 | Q15427, P38159, P61978, P11142 | SF3B4, RBMX, HNRPK, HSPA8 | More | |
| Atorvastatin | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | |
| Atorvastatin | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
| Atorvastatin | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | |
| Atorvastatin | hsa04020 | Calcium signaling pathway | 6.50E-04 | 6 | Q96DU7, P45880, Q13557, P21860, P51828, P23634 | ITPKC, VDAC2, CAMK2D, ERBB3, ADCY7, ATP2B4 | More | |
| Atorvastatin | hsa04022 | cGMP-PKG signaling pathway | 4.72E-02 | 4 | Q99941, P23634, P51828, P45880 | CREBL1, ATP2B4, ADCY7, VDAC2 | More | |
| Atorvastatin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | |
| Atorvastatin | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | |
| Atorvastatin | hsa04064 | NF-kappa B signaling pathway | 2.15E-02 | 7 | P14778, P19174, Q04759, P06239, P09341, P19875, Q06643 | IL1R1, PLCG1, PRKCQ, LCK, CXCL1, CXCL2, LTB | More | |
| Atorvastatin | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
| Atorvastatin | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | |
| Atorvastatin | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | |
| Atorvastatin | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | |
| Atorvastatin | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Atorvastatin | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | |
| Atorvastatin | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Atorvastatin | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.98E-02 | 4 | P51828, Q99941, Q13557, P23634 | ADCY7, CREBL1, CAMK2D, ATP2B4 | More | |
| Atorvastatin | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | |
| Atorvastatin | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Atorvastatin | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Atorvastatin | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | |
| Atorvastatin | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | |
| Atorvastatin | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
| Atorvastatin | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | |
| Atorvastatin | hsa04659 | Th17 cell differentiation | 1.43E-04 | 11 | P25963, Q04759, P19174, P06239, P14784, P14778, Q9UL17, P84022, Q13485, P07766, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, CD3E, CD247 | More | |
| Atorvastatin | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | |
| Atorvastatin | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | |
| Atorvastatin | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.62E-04 | 8 | P14778, P01584, P51828, Q13557, P19174, P42338, P24723, Q04759 | IL1R1, IL1B, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCH, PRKCQ | More | |
| Atorvastatin | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Atorvastatin | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | |
| Atorvastatin | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | |
| Atorvastatin | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Atorvastatin | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | |
| Atorvastatin | hsa04925 | Aldosterone synthesis and secretion | 5.19E-03 | 4 | Q99941, P51828, Q13557, P23634 | CREBL1, ADCY7, CAMK2D, ATP2B4 | More | |
| Atorvastatin | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Atorvastatin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Atorvastatin | hsa04934 | Cushing syndrome | 3.48E-03 | 4 | Q99941, P51828, O15169, Q13557 | CREBL1, ADCY7, AXIN1, CAMK2D | More | |
| Atorvastatin | hsa04971 | Gastric acid secretion | 1.48E-02 | 3 | P51828, P15311, Q13557 | ADCY7, VIL2, CAMK2D | More | |
| Atorvastatin | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | |
| Atorvastatin | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Atorvastatin | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
| Atorvastatin | hsa05010 | Alzheimer disease | 2.07E-02 | 7 | Q92542, P05496, P12074, O75460, P01584, O15169, P45880 | NCSTN, ATP5G1, COX6A1, ERN1, IL1B, AXIN1, VDAC2 | More | |
| Atorvastatin | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | |
| Atorvastatin | hsa05020 | Prion disease | 1.81E-02 | 7 | P01584, P46531, P11142, P05496, P12074, P45880, Q99941 | IL1B, NOTCH1, HSPA8, ATP5G1, COX6A1, VDAC2, CREBL1 | More | |
| Atorvastatin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | |
| Atorvastatin | hsa05132 | Salmonella infection | 2.04E-02 | 4 | P25963, Q13489, P10415, Q9BQS8 | NFKBIA, BIRC3, BCL2, FYCO1 | More | |
| Atorvastatin | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | |
| Atorvastatin | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Atorvastatin | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | |
| Atorvastatin | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Atorvastatin | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | |
| Atorvastatin | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Atorvastatin | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | |
| Atorvastatin | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | |
| Atorvastatin | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Atorvastatin | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Atorvastatin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | |
